{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:37:30Z","timestamp":1785191850588,"version":"3.55.0"},"reference-count":31,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,1,7]],"date-time":"2013-01-07T00:00:00Z","timestamp":1357516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2013,5]]},"abstract":"<jats:sec>\n                    <jats:title>What's known on the subject? and What does the study add?<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            Hypogonadism affects an estimated 2\u20134 million men in the USA, but only 5% receive treatment. Testosterone replacement therapy reduces the effects of testosterone deficiency on sexual function, mood and energy in hypogonadal patients. Long\u2010term hypogonadism management requires testosterone treatment to restore serum concentrations of testosterone and its active metabolites, within physiological ranges; a testosterone preparation that achieves physiological plasma concentrations without supra\u2010physiological escape is a preferred option. A previous 1\u2010year study European clinical study showed the efficacy and safety of a transdermal testosterone patch (Testopatch\n                            <jats:sup>\u00ae<\/jats:sup>\n                            ).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            The present study shows the long\u2010term (6\u2010year) safety and efficacy of Testopatch in patients with primary or secondary hypogonadism. We show that, over the long\u2010term, Testopatch was associated with no relevant changes in\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            concentration and\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            velocity, or any significant prostate risks (there were no cases of prostate cancer).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            To assess the change in prostate\u2010specific antigen (\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            ) concentrations in patients with primary or secondary hypogonadism, receiving transdermal testosterone.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            This was an interventional, 6\u2010year study, conducted in Urology and Endocrinology centres in\n                            <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>\n                            elgium,\n                            <jats:styled-content style=\"fixed-case\">F<\/jats:styled-content>\n                            rance,\n                            <jats:styled-content style=\"fixed-case\">G<\/jats:styled-content>\n                            ermany, the\n                            <jats:styled-content style=\"fixed-case\">N<\/jats:styled-content>\n                            etherlands and\n                            <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>\n                            pain.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Participants were primary (48%) or secondary (52%) hypogonadal patients who received two 60\u2009cm\n                            <jats:sup>2<\/jats:sup>\n                            testosterone patches (Testopatch\n                            <jats:sup>\u00ae<\/jats:sup>\n                            ), delivering 4.8\u2009mg of testosterone per day, applied every 2 days.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            During treatment, total testosterone (\n                            <jats:styled-content style=\"fixed-case\">TT<\/jats:styled-content>\n                            ), dihydrotestosterone, oestradiol and,\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            concentrations were measured in a centralised laboratory every 3 months during the first year, and every 6 months thereafter.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            In all, 200 patients [mean (sd) age 41.0\u2009(12.5) years, body weight 82.5\u2009(13.7)\u2009kg, height 177.2\u2009(9.3)\u2009cm, body mass index 26.2\u2009(3.4)\u2009kg\/m\n                            <jats:sup>2<\/jats:sup>\n                            ] were treated with transdermal testosterone patches.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>In all, 161 patients completed the 1\u2010year study and 115 entered into a 5\u2010year study extension; 51 patients completed the sixth year of the study.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            The mean baseline concentrations of\n                            <jats:styled-content style=\"fixed-case\">TT<\/jats:styled-content>\n                            and\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            were 1.4\u2009ng\/mL and 0.47\u2009ng\/mL, respectively;\n                            <jats:styled-content style=\"fixed-case\">TT<\/jats:styled-content>\n                            serum concentrations &gt;3\u2009ng\/mL were achieved in 85% of patients and fluctuated between 4.4 and 6.0\u2009ng\/mL.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            At each successive 6\u2010month time point, mean the\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            values were 0.60, 0.67, 0.76, 0.70, 0.61, 0.68, 0.64, 0.71, 0.75, 0.74, 1.01, 0.78, 0.80\u2009ng\/mL, respectively. The mean\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            velocity was negligible (0.00\u20130.03\u2009ng\/mL\/year) from 30 months to the end of the trial, except for a value of 0.08 at 60 months. Seven patients had a\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            concentration of &gt;4\u2009ng\/mL due to a sharp\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            increase. Six of these patients had prostatitis and\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            concentrations returned to previous levels with appropriate treatment. No prostate cancer was reported during the trial.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>These data support a strong safety profile for Testopatch, even at the highest registered dosage.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2012.11514.x","type":"journal-article","created":{"date-parts":[[2013,1,7]],"date-time":"2013-01-07T09:33:31Z","timestamp":1357551211000},"page":"880-890","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Prostate\u2010specific antigen (\n                    <scp>PSA<\/scp>\n                    ) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment"],"prefix":"10.1111","volume":"111","author":[{"given":"Jean\u2010Pierre","family":"Raynaud","sequence":"first","affiliation":[{"name":"Universit\u00e9 Pierre et Marie Curie  4 place Jussieu 75252 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Gardette","sequence":"additional","affiliation":[{"name":"40 rue de Chezy 92200 Neuilly\/seine France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Rollet","sequence":"additional","affiliation":[{"name":"Institut Rh\u00f4ne alpin  M\u00e9dicentre Val Ouest 69130 Ecully France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Jacques","family":"Legros","sequence":"additional","affiliation":[{"name":"CHR Citadelle Universit\u00e9 de Li\u00e8ge  Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,1,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.74.6.1221"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1939-4640.1992.tb00319.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(18)30072-0"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1997.3071113.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.8.2670"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-08-0601"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1994.tb03929.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.19.2351"},{"key":"e_1_2_8_10_1","first-page":"623","article-title":"Enhanced transdermal delivery of testosterone across non scrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men","volume":"85","author":"Meikle AW","year":"1992","journal-title":"J Clin Endocrinol Metabol"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2007.10.010"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra022251"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2004.04.008"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2005.052126"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2007.087312"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.3109\/13685539909003173"},{"key":"e_1_2_8_17_1","volume-title":"Centre for Drug Evaluation and Research. Skin Irritation and Sensitization Testing of Generic Transdermal Drug Products","author":"Food and Drug Administration","year":"1999"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2008.02.004"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2009.03.025"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2008.00951.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1046-199X(97)90003-8"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(98)80093-3"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(96)00445-1"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.09.024"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-128X(75)80023-7"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3901394"},{"key":"e_1_2_8_27_1","first-page":"301","article-title":"Comparison of oral versus transdermal testosterone supplementation in hypogonadal men","volume":"2","author":"Raynaud JP","year":"2010","journal-title":"Horm Mol Biol Clin Invest"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.2990230203"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.11.084"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.pcan.4500839"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2009.01.014"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2007.08.002"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2012.11514.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2012.11514.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:37:33Z","timestamp":1761748653000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2012.11514.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,7]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["10.1111\/j.1464-410X.2012.11514.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2012.11514.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,7]]},"assertion":[{"value":"2013-01-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}